Association of the CYP3A5 polymorphism (6986G>A) with blood pressure and hypertension.

The cytochrome P450 family 3 subfamily A polypeptide 5 (CYP3A5) gene has been implicated in the regulation of blood pressure (BP) and thus, may serve as a potential risk factor for the development of hypertension. However, current results regarding the association between CYP3A5 single nucleotide polymorphisms and BP/hypertension have been inconsistent. In this study, we performed a meta-analysis to evaluate the association between the CYP3A5 rs776746 (6986G>A) polymorphism and BP/hypertension. Ten studies (representing 2799 cases and 6794 controls) were included to determine the association of this single nucleotide polymorphism with hypertension, and 12 studies (9076 subjects) were included to determine the association of this single nucleotide polymorphism with BP. Overall, no associations were observed between the rs776746 polymorphism and BP/hypertension. In subgroup analysis, CYP3A5*1 carriers had lower systolic BP, compared with non-carriers in white populations (mean difference=-1.322, 95% confidence interval -2.401 to -0.242 mm Hg, P=0.016). This meta-analysis suggested a modestly significant association between the CYP3A5 rs776746 polymorphism and systolic BP in white populations. Given the limited sample size, additional studies are necessary to investigate the role of CYP3A5 in the regulation of BP and the pathogenesis of hypertension.